CN1907357A - 一种调节血压和血脂的复方花粉精口服液及制备方法 - Google Patents
一种调节血压和血脂的复方花粉精口服液及制备方法 Download PDFInfo
- Publication number
- CN1907357A CN1907357A CNA2006101044981A CN200610104498A CN1907357A CN 1907357 A CN1907357 A CN 1907357A CN A2006101044981 A CNA2006101044981 A CN A2006101044981A CN 200610104498 A CN200610104498 A CN 200610104498A CN 1907357 A CN1907357 A CN 1907357A
- Authority
- CN
- China
- Prior art keywords
- extract
- oral liquid
- pollen
- medicine
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 43
- 239000008280 blood Substances 0.000 title claims abstract description 36
- 210000004369 blood Anatomy 0.000 title claims abstract description 36
- 150000001875 compounds Chemical class 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000036772 blood pressure Effects 0.000 title abstract description 21
- 230000001105 regulatory effect Effects 0.000 title abstract 4
- 239000000284 extract Substances 0.000 claims abstract description 64
- 239000008367 deionised water Substances 0.000 claims abstract description 21
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000012530 fluid Substances 0.000 claims abstract description 18
- 229940038481 bee pollen Drugs 0.000 claims abstract description 14
- 238000001914 filtration Methods 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 74
- 241000628997 Flos Species 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 8
- 230000029865 regulation of blood pressure Effects 0.000 claims description 8
- 239000003643 water by type Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 4
- 230000001186 cumulative effect Effects 0.000 claims description 4
- 230000003068 static effect Effects 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 21
- 150000002632 lipids Chemical class 0.000 abstract description 8
- 208000000418 Premature Cardiac Complexes Diseases 0.000 abstract description 3
- 206010003119 arrhythmia Diseases 0.000 abstract description 3
- 230000006793 arrhythmia Effects 0.000 abstract description 3
- 210000004351 coronary vessel Anatomy 0.000 abstract description 3
- 230000000916 dilatatory effect Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 208000030159 metabolic disease Diseases 0.000 abstract description 2
- 235000012907 honey Nutrition 0.000 abstract 3
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 abstract 1
- 210000002421 cell wall Anatomy 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 description 35
- 238000011282 treatment Methods 0.000 description 27
- 208000031226 Hyperlipidaemia Diseases 0.000 description 26
- 108010007622 LDL Lipoproteins Proteins 0.000 description 20
- 102000007330 LDL Lipoproteins Human genes 0.000 description 20
- 229940079593 drug Drugs 0.000 description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 13
- 206010008190 Cerebrovascular accident Diseases 0.000 description 12
- 208000006011 Stroke Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000034994 death Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000029078 coronary artery disease Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 102000015779 HDL Lipoproteins Human genes 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000001631 hypertensive effect Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 3
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 235000003935 Hippophae Nutrition 0.000 description 3
- 241000229143 Hippophae Species 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940127088 antihypertensive drug Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- 239000002981 blocking agent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000003516 hyperlipidaemic effect Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 206010010164 Hypertension complications Diseases 0.000 description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 241000241413 Propolis Species 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960002198 irbesartan Drugs 0.000 description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229940069949 propolis Drugs 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000009978 visual deterioration Effects 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 241000218628 Ginkgo Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- -1 azoles piperazines Chemical class 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000010225 buchang naoxintong Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000009465 diaoxinxuekang Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 239000010212 ginaton Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003814 hair luster Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940095570 lescol Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229940080268 lotensin Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008911 qingzhi Substances 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 239000010068 shuxuening Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000008588 xue-zhi-ning Substances 0.000 description 1
- 239000008802 xuezhikang Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
年龄组 | <40 | 41~50 | 50~60 | >60 | 总计 |
例数 | 13 | 43 | 261 | 46 | 363 |
病程 | <1年 | 1~3年 | 3~5年 | 5~10年 | >10年 | 总计 |
例数 | 8 | 72 | 162 | 69 | 52 | 363 |
项目 | 治疗前平均血压mmHg | 治疗后平均血压mmHg | P值 |
单纯高血压者 | (140±20)/(90±10) | (120±5)/(74±8) | P<0.01 |
高血压兼有高血脂者 | (142±20)/(90±10) | (125±5)/(75±8) | P<0.01 |
项目 | 治疗前(mmol/L) | 治疗后(mmol/L) | P值 |
胆固醇 | 7.19±0.71 | 6.49±0.88 | <0.01 |
甘油三脂 | 2.18±0.63 | 1.84±0.47 | <0.01 |
高密度脂蛋白 | 1.20±0.23 | 1.29±0.18 | <0.05 |
低密度脂蛋白 | 3.41±0.54 | 3.27±0.48 | <0.05 |
项目 | 治疗前(mmol/L) | 治疗后(mmol/L) | P值 |
胆固醇 | 7.15±0.89 | 6.40±0.07 | <0.01 |
甘油三脂 | 2.22±0.70 | 1.76±0.52 | <0.01 |
高密度脂蛋白 | 1.17±0.24 | 1.34±0.20 | <0.05 |
低密度脂蛋白 | 3.45±0.34 | 3.32±0.52 | <0.05 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101044981A CN1907357B (zh) | 2006-08-11 | 2006-08-11 | 一种调节血压和血脂的复方花粉精口服液及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101044981A CN1907357B (zh) | 2006-08-11 | 2006-08-11 | 一种调节血压和血脂的复方花粉精口服液及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1907357A true CN1907357A (zh) | 2007-02-07 |
CN1907357B CN1907357B (zh) | 2010-04-14 |
Family
ID=37698694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101044981A Active CN1907357B (zh) | 2006-08-11 | 2006-08-11 | 一种调节血压和血脂的复方花粉精口服液及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1907357B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101804111A (zh) * | 2010-05-10 | 2010-08-18 | 北京华仁堂药物科技有限公司 | 治疗高血压的中药药物及其制备方法 |
CN101757123B (zh) * | 2009-09-23 | 2011-11-09 | 苏州派腾生物医药科技有限公司 | 一种治疗高血压的组合物及其制备方法 |
CN104547779A (zh) * | 2015-02-09 | 2015-04-29 | 王士国 | 慢性动脉硬化症降脂通脉药剂及制备方法 |
CN104706790A (zh) * | 2015-02-06 | 2015-06-17 | 宁波高新区零零七工业设计有限公司 | 一种治疗高血压的中药 |
CN105832860A (zh) * | 2016-05-04 | 2016-08-10 | 昆明理工大学 | 一种抗高原反应的黄腐酸口服液及其制备方法 |
CN107485020A (zh) * | 2017-08-18 | 2017-12-19 | 武汉华士特工业生物技术开发有限公司 | 一种具有美白功能的口服液及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1229127C (zh) * | 2002-12-31 | 2005-11-30 | 中国中医药科技开发交流中心 | 一种防治高血压的药物组合物及其质量控制方法和用途 |
CN1241602C (zh) * | 2004-01-14 | 2006-02-15 | 王根文 | 治疗心脑血管疾病的口服药酒 |
-
2006
- 2006-08-11 CN CN2006101044981A patent/CN1907357B/zh active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101757123B (zh) * | 2009-09-23 | 2011-11-09 | 苏州派腾生物医药科技有限公司 | 一种治疗高血压的组合物及其制备方法 |
CN101804111A (zh) * | 2010-05-10 | 2010-08-18 | 北京华仁堂药物科技有限公司 | 治疗高血压的中药药物及其制备方法 |
CN101804111B (zh) * | 2010-05-10 | 2011-12-07 | 北京华仁堂药物科技有限公司 | 治疗高血压的中药药物及其制备方法 |
CN104706790A (zh) * | 2015-02-06 | 2015-06-17 | 宁波高新区零零七工业设计有限公司 | 一种治疗高血压的中药 |
CN104547779A (zh) * | 2015-02-09 | 2015-04-29 | 王士国 | 慢性动脉硬化症降脂通脉药剂及制备方法 |
CN105832860A (zh) * | 2016-05-04 | 2016-08-10 | 昆明理工大学 | 一种抗高原反应的黄腐酸口服液及其制备方法 |
CN107485020A (zh) * | 2017-08-18 | 2017-12-19 | 武汉华士特工业生物技术开发有限公司 | 一种具有美白功能的口服液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1907357B (zh) | 2010-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100382839C (zh) | 一种治疗冠心病的中药组合物 | |
CN1907357B (zh) | 一种调节血压和血脂的复方花粉精口服液及制备方法 | |
CN101037651A (zh) | 灵芝香蕈保健酒及其制作方法 | |
CN101822789B (zh) | 一种治疗原发性高血压的降压药 | |
CN102526276B (zh) | 一种降压药物组合物及其制备方法 | |
CN103083315A (zh) | 一种中药成分组合物及其用途 | |
CN1698804A (zh) | 一种治疗胸痹、心悸的中药制剂及制备方法 | |
CN102178798A (zh) | 一种用于降低血脂、防治心脑血管疾病的制剂 | |
CN102772611A (zh) | 一种中药组合物及其制备方法和应用 | |
CN102343049B (zh) | 一种治疗肝阳上亢型高血压病的中药胶囊 | |
CN1990033A (zh) | 一种治疗高血压、血稠、动脉硬化的药物 | |
CN1565524A (zh) | 一种治疗老年性痴呆的药物及其制备方法 | |
CN103479895A (zh) | 一种舒心清脑中药组合物 | |
CN1111054C (zh) | 一种治疗中风的药物及其生产方法 | |
CN1186067C (zh) | 治疗急性筋伤的药物及其制备方法 | |
CN1296087C (zh) | 用于治疗中风中经络风痰瘀阻的复方胶囊及其制备方法 | |
CN102225155B (zh) | 一种治疗肺纤维化的药物组合物 | |
CN1045892C (zh) | 防治冠心病心绞痛的中药制剂 | |
CN110548099A (zh) | 一种用于治疗冠心病稳定型心绞痛的中药组合物及其制备方法 | |
CN1745768A (zh) | 一种含黄芪的药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1686514A (zh) | 治疗焦虑症、抑郁症的中药制剂及其生产方法 | |
CN1253188C (zh) | 一种治疗高血压的药物及其制备方法 | |
CN103385963A (zh) | 治疗冠心病引发心绞痛的中药制剂 | |
CN102430040A (zh) | 一种治疗糖尿病的药物 | |
CN102309561A (zh) | 一种用于预防和治疗痛风性关节炎及高尿酸血症的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: DONGNING PHARMACEUTICAL CO., LTD., LIAONING PROVIN Free format text: FORMER OWNER: FU JIANXI Effective date: 20120419 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 712100 XI AN, SHAANXI PROVINCE TO: 123000 FUXIN, LIAONING PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120419 Address after: 123000 hi tech Industrial Park, Fuxin, Liaoning Patentee after: Dongning Pharmaceutical Co., Ltd., Liaoning Province Address before: 712100 No. 5-131, autumn garden, science education street, Yangling demonstration area, Shaanxi, Xi'an Patentee before: Fu Jianxi |